Accendra Health is a highly leveraged but potentially explosive home-care turnaround, where recurring chronic-care demand and post-divestiture margin expansion could create major upside if debt, payor concentration, and reimbursement risks are controlled.
Overview
Accendra Health has transformed from Owens & Minor’s legacy distribution model into a focused home-based care company after selling its low-margin P&HS business for $375 million. The remaining Apria and Byram platforms provide recurring direct-to-patient respiratory equipment, sleep apnea devices, diabetes supplies, urology, ostomy, wound care, and incontinence products across all 50 states. The investment case rests on high-margin recurring care, national scale, chronic-disease demand, and successful post-divestiture execution, but the company remains highly leveraged and exposed to payor concentration.